Milly Gaines
Fen-phen was a weight-loss drug that combined fenfluramine and phentermine. Marketed as a 'miracle' pill, it gained rapid popularity in the 1990s, but was later withdrawn from the market due to severe side effects, including heart valve damage and pulmonary hypertension. Despite never being approved by the FDA for combined use, fen-phen was prescribed as a treatment for severe obesity and even some drug and alcohol addictions. The fallout from fen-phen's side effects resulted in a wave of litigation, with thousands of injured persons pursuing legal action and settlements.
| Characteristics | Values |
|---|---|
| Generic Name | Fenfluramine/Phentermine |
| Brand Name | Fen-Phen |
| Type | Anti-obesity medication |
| Availability | No longer widely available |
| Side Effects | Pulmonary hypertension, heart valve problems, fast heart rate, high blood pressure, trouble sleeping, dizziness, restlessness |
| Lawsuits | Over 50,000 product liability lawsuits, total liability estimated to be as high as $14 billion |
Explore related products
What You'll Learn
Fen-phen's popularity as a miracle weight-loss drug
Fen-phen, the combination of fenfluramine and phentermine, gained immense popularity as a miracle weight-loss drug in the early 1990s. Fenfluramine was first introduced in the 1970s as an anti-obesity medication, but it was not well-received due to temporary weight loss and side effects like nausea and anxiety.
In 1979, Dr. Michael Weintraub of the University of Rochester had the idea to combine fenfluramine with phentermine, another weight-loss drug. This combination was tested and found to be more effective in promoting weight loss and treating obesity without causing the same side effects as previous diet drugs. The 1984 study found an average weight loss of 7.5 kg in 24 weeks, compared to 4.4 kg under a placebo.
Despite not being approved by the FDA, the combination drug gained immense popularity in the 1990s as a miracle weight-loss solution. It was heavily marketed and soon became known as "Fen-Phen," with thousands of prescriptions being written. The drug combination was seen as a magic pill for the national obesity epidemic, and its popularity soared based on a single study involving just 121 patients.
However, as Fen-Phen's popularity rose, so did concerns about its safety. In 1996, a 30-year-old woman developed heart problems after taking Fen-Phen for a month and subsequently died in February 1997. This incident, along with other reports of valvular heart disease and pulmonary hypertension, primarily in women who had taken Fen-Phen, led to increased scrutiny and eventual withdrawal of the drug from the market in September 1997.
Sugar Alcohols and the Atkins Diet: How Much?
You may want to see also
Explore related products
Fen-phen's side effects and health risks
Fen-phen, a combination of fenfluramine and phentermine, was a popular weight-loss therapy in the 1990s. While the FDA approved fenfluramine and phentermine for separate use, they never approved them to be used in combination. Despite this, it gained popularity as a wonder drug that could help people lose weight faster than diet and exercise.
Fen-phen has been linked to several serious side effects and health risks, leading to its withdrawal from the market in 1997. Here are some of the reported side effects and health risks associated with fen-phen:
Valvular Heart Disease (VHD): Fen-phen has been linked to valvular heart disease, which involves deterioration of the heart valves, specifically the aortic and mitral valves on the left side and the pulmonary and tricuspid valves on the right side. This can lead to potentially fatal heart problems, including pulmonary hypertension and mitral valve dysfunction.
Primary Pulmonary Hypertension (PPH) or Pulmonary Arterial Hypertension (PAH): PPH/PAH is a serious condition caused by scarring and fibrosis in the pulmonary arteries, which carry deoxygenated blood from the heart to the lungs. This scarring prevents blood cells from effectively absorbing oxygen, leading to shortness of breath and lightheadedness during activity. PPH/PAH can ultimately result in heart failure and death, with women being more susceptible.
Cardiac Risks: Fen-phen has been associated with cardiac risks, including an increased heart rate (palpitations) and potentially fatal pulmonary hypertension. Follow-up studies showed that for people who took the combination for three months or less, the rate of heart valve complications was less than 3%. However, the overall risk of heart-related issues was still considered unacceptably high.
Other Side Effects: Phentermine, one of the components of fen-phen, can cause side effects such as a fast heart rate, high blood pressure, trouble sleeping, dizziness, and restlessness. It may also be habit-forming, especially if not taken as directed. Additionally, alcohol consumption can enhance phentermine's side effects. Phentermine is also not recommended for pregnant women as it can harm the unborn baby.
The side effects and health risks associated with fen-phen led to its withdrawal from the market and sparked a wave of lawsuits and settlements. If you or anyone you know has taken fen-phen and experienced adverse effects, it is important to seek medical advice and explore legal options.
Cleanse Diet Drinks: Are They Safe?
You may want to see also
Explore related products
Fen-phen's withdrawal from the market
Fen-phen, a combination of fenfluramine and phentermine, was an anti-obesity medication that gained immense popularity as a "wonder drug" or "miracle medicine" in the early 1990s. Despite not being approved by the FDA for use in combination, it was heavily marketed as a way to lose weight faster than with diet and exercise alone.
However, in 1996, a 30-year-old woman developed heart problems after taking fen-phen for a month and subsequently died in February 1997. This tragic incident, along with other reports of valvular heart disease and pulmonary hypertension, primarily in women using fen-phen, led to increased scrutiny and concern.
In August 1997, a paper in the New England Journal of Medicine from the Mayo Clinic discussed clinical findings in 24 people who had taken fen-phen, suggesting a possible correlation between mitral valve dysfunction and the use of these anorectic agents. The FDA received additional reports of valvular heart disease and requested its withdrawal from the market in September 1997. The manufacturers of fenfluramine and dexfenfluramine, responding to the FDA's request, withdrew the drugs from the market.
The withdrawal of fen-phen from the market in 1997 marked a turning point in the understanding and regulation of weight-loss treatments. It highlighted the potential dangers of combining certain drugs and the importance of thorough evaluation and monitoring of medications, especially those intended for long-term use.
The fallout from the fen-phen debacle included legal damages exceeding $13 billion and over 50,000 product liability lawsuits filed by alleged victims. It also sparked discussions about the role and responsibility of doctors in prescribing such medications and the need for more stringent approval and monitoring processes for drugs with potential serious side effects.
Boost Diet Broth: Beef Up the Flavor
You may want to see also
Explore related products
Fen-phen litigation and lawsuits
Fen-phen, a combination of fenfluramine and phentermine, was an anti-obesity medication sold in the early 1990s. It was marketed by American Home Products (AHP) as Pondimin and Redux. However, the drug was linked to serious side effects, including potentially fatal pulmonary hypertension and heart valve problems, which led to its withdrawal from the market in 1997. This prompted a wave of litigation and lawsuits against AHP.
In 1996, doctors wrote 18 million prescriptions for fen-phen and its cousin drug, Redux. However, soon after, concerns began to emerge about the safety of these drugs. Doctors at the Mayo Clinic reported heart valve defects in patients taking fen-fen, and in 1997, a 30-year-old woman died of heart problems after taking the drug for a month. This led to further investigations and the eventual withdrawal of the drugs from the market.
As a result of the harmful side effects of fen-phen, AHP faced thousands of lawsuits from injured consumers. In 1999, AHP agreed to pay $3.75 billion in total to settle claims from people who suffered heart valve injuries or lung problems due to the drug. This settlement was unusual as it allowed consumers to "opt out" and pursue individual cases at three separate points. Despite this settlement, AHP continued to face additional lawsuits, and by 2005, more than 50,000 product liability lawsuits had been filed, with total liability estimated to be as high as $14 billion.
The fen-phen litigation highlighted the potential dangers of prescription weight-loss medications and the importance of thorough testing and monitoring of side effects. It also demonstrated the public's growing distaste for corporate deceit and the willingness of juries to award significant damages to those harmed by defective products.
How Beef-Free Diets Help Fight Climate Change
You may want to see also
Explore related products
Fen-phen's manufacturer, Wyeth
Fen-phen, a combination of the drugs fenfluramine and phentermine, was developed in the early 1970s by American Home Products, later known as Wyeth. The drug was initially marketed as Pondimin but failed to gain popularity due to minor weight loss results and side effects like nausea and anxiety.
In the 1990s, fenfluramine was combined with phentermine and heavily marketed as a miracle weight-loss drug. This combination was not approved by the FDA. Despite this, it gained immense popularity as a wonder drug that could help people lose weight faster than diet and exercise.
In 1996, a 30-year-old woman developed heart problems after taking fen-phen for a month and subsequently died in February 1997. This incident, along with other reports of valvular heart disease and pulmonary hypertension, primarily in women, led to the withdrawal of fen-phen from the market in September 1997. The FDA requested that the manufacturers of fenfluramine and dexfenfluramine stress the potential risk to the heart in the drugs' labelling and packaging inserts.
Wyeth, the manufacturer of fen-phen, faced a wave of litigation, with more than 50,000 product liability lawsuits filed by alleged victims. The total liability was estimated to be as high as $14 billion, with Wyeth setting aside $21.1 billion to cover the cost of the lawsuits. The company offered settlements ranging from $5,000 to $200,000 to some of those who had sued, but thousands of injured persons rejected these offers.
Heal Your Gut, Heal Your Skin: Diet for HS
You may want to see also
Frequently asked questions
Phen fen, also known as fen-phen, is the popular name given to the combination of appetite suppressants fenfluramine and phentermine.
Fen-phen was linked to severe heart and lung damage, including valvular heart disease and pulmonary hypertension.
While the FDA approved fenfluramine and phentermine for separate use, the agency never approved them to be used in combination with one another.
Fen-phen was removed from the market in 1997 after it was linked to severe heart and lung damage.
Yes, there were. In 2005, American Lawyer magazine reported that more than 50,000 product liability lawsuits had been filed by alleged fen-phen victims, with total liability estimated to be as high as $14 billion.
